The mRNA-1273 SARS-CoV-2 vaccine had high short-term efficacy, but its medium-term efficacy and safety are not known. https://nej.md/2YfXzla | The New England Journal of Medicine

Preliminary data indicated high efficacy of an mRNA-based vaccine developed in collaboration between Moderna and the NIAID. The vaccine has now been evaluated in an ongoing phase 3 randomized, controlled trial. New research findings are summarized in a short video. https://nej.md/3tstdX9 | The New England Journal of Medicine

Vaccinating children against Covid-19 is needed both for their own protection and to help control the ongoing pandemic. New research findings on the mRNA-1273 vaccine are summarized in a short video. https://nej.md/3sT991s | The New England Journal of Medicine